Overview
This patent describes a pharmacological approach using orally administered low-dose type I and type III interferons to reduce muscle injury and stabilize skeletal muscle. Filed in July 2014 and granted in May 2017, the application—by inventors based in Edmond, OK—discloses compositions (incl...
10-12-2025 03:27 PM
